Fig. 1 · Structure

Documents & Downloads

PQ 401

Cat. No. A11951 CAS 196868-63-0

IGF-1R inhibitor

PQ 401 is a cell-permeable phenylquinolinyl-urea compound that inhibits IGF-1R autophosphorylation.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
IGF-1R <1 μM

Cellular Effect

Cell Line Activity Value Description Reference
BJ EC50 > 25 μM Cytotoxicity against human BJ cells after 72 hrs by Cell titer-glo assay [PMID: 21243104]
HEK293 EC50 > 25 μM Cytotoxicity against human HEK293 cells after 72 hrs by Cell titer-glo assay [PMID: 21243104]
HepG2 EC50 > 25 μM Cytotoxicity against human HepG2 cells after 72 hrs by Cell titer-glo assay [PMID: 21243104]
MCF7 IC50 < 1 μM Inhibition of IGF1R autophosphorylation in human MCF7 cells by Western blot analysis [PMID: 19610618]
MCF7 IC50 12 μM Inhibition of IGF1R autophosphorylation in human MCF7 cells by ELISA [PMID: 19610618]
Raji EC50 > 25 μM Cytotoxicity against human Raji cells after 72 hrs by Cell titer-glo assay [PMID: 21243104]

PQ 401 Research Summary

This section summarizes 2 in vitro studies of PQ 401 from 1 published reference. In vitro models include HeLa S3.

PQ 401 In Vitro Studies

In HeLa S3 cells, treatment with 5 µM PQ 401 resulted in unaligned chromosomes in more than 45% of M-phase cells, compared with 22% in the DMSO solvent control. In a separate viability study, PQ 401 treatment at 0.3–10 µM for 48 h reduced cell numbers in a concentration-dependent manner. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Chromosome alignment in HeLa cells

Cell-based study · HeLa S3 [1]

HeLa S3 cells were treated with 5 µM PQ401 or solvent control (DMSO) for 24 h. During the last 20 h of inhibitor treatment, cells were treated with 6 µM RO-3306 in the presence of inhibitors. M-phase cells: only 22% of solvent (dimethyl sulfoxide) control cells did not align their chromosomes and were classified as P/PM; more than 45% of cells did not align their chromosomes upon treatment with 5 µM PQ401.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
M-phase cells: prophase/prometaphse (P/PM)prophase/prometaphase cells 5 µM PQ401: more than 45% of M-phase cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 µM
Exposure duration
for 24 h; During the last 20 h of inhibitor treatment; After 50 min, cells were fixed
Method
in the presence of inhibitors
Vehicle
DMSO
Co-treatment
Other interventions in this design: RO-3306 6 µM. Compound effect isolated by the comparison: solvent control (DMSO).
Methods and source locations

Compound reported in the paper: PQ 401

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.3. Delay in M-Phase Progression by IGF1R Inhibitors (S54); 4. Materials and Methods > 4.2. Chemicals (S108); 4. Materials and Methods > 4.4. Antibodies (S112); 4. Materials and Methods > 4.5. Immunofluorescence Microscopy (S117); Figure 5 legend (S217, S218, S220, S221)

M-phase cells: prophase/prometaphse (P/PM): M-phase cells: prophase/prometaphse (P/PM); comparator: solvent control (DMSO) — 2. Results > 2.3. Delay in M-Phase Progression by IGF1R Inhibitors (S54); Figure 5 legend (S221)

Cell number response in HeLa cells

Cell-based study · HeLa S3 [1]

HeLa S3 cells were cultured with inhibitors at 0.3–10 µM for 48 h, with DMSO as the solvent control. Inhibitor treatment reduced cell numbers in a concentration-dependent manner.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability was assayed using a water-soluble tetrazolium salt (WST-8)Reported result The cell numbers were reduced by inhibitor treatment in a concentration-dependent manner[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.3–10 µM
Exposure duration
48 h
Method
cultured with the IGF1R inhibitors
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: PQ 401

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.3. Delay in M-Phase Progression by IGF1R Inhibitors (S49); 4. Materials and Methods > 4.9. Proliferation Assay (S137, S138, S140); Figure 5 legend (S212, S213)

cell viability was assayed using a water-soluble tetrazolium salt (WST-8): cell viability was assayed using a water-soluble tetrazolium salt (WST-8); comparator: DMSO was added to the culture at 0.1% as a solvent control — 2. Results > 2.3. Delay in M-Phase Progression by IGF1R Inhibitors (S49); Figure 5 legend (S212)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 196868-63-0
Applications IGF-1R inhibitor
Formula C18H16ClN3O2
Molecular Weight 341.79
SMILES
CC1=NC2=CC=CC=C2C(=C1)NC(=O)NC3=C(C=CC(=C3)Cl)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 30 mg/mL (87.77 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PQ 401 Research References

  1. [1] Yamagishi A, Ikeda Y, Ikeuchi M, et al. Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation. Int J Mol Sci (2020). PMID: 32033461 DOI: 10.3390/ijms21031058 Source material

Added to your cart

View Cart Checkout
Loading...